Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has announced new stock option grants to six employees. The grants, approved by the Compensation Committee under the company's 2022 Inducement Plan, total 285,000 shares with an exercise price of $5.96 per share.
The stock options feature a four-year vesting schedule, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the following three years. The options have a 10-year term and are contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining the company.
Olema Pharmaceuticals (Nasdaq: OLMA), un'azienda biofarmaceutica in fase clinica focalizzata su terapie mirate per il cancro al seno, ha annunciato nuove concessioni di opzioni su azioni a sei dipendenti. Le concessioni, approvate dal Comitato per la Retribuzione sotto il Piano di Induzione 2022 dell'azienda, ammontano a 285.000 azioni con un prezzo di esercizio di 5,96 $ per azione.
Le opzioni su azioni presentano un programma di maturazione di quattro anni, con il 25% che matura al primo anniversario e il restante 75% che matura in 36 rate mensili uguali nei successivi tre anni. Le opzioni hanno un termine di 10 anni e sono subordinate a un impiego continuo. Questa concessione è stata effettuata in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per i nuovi dipendenti che si uniscono all'azienda.
Olema Pharmaceuticals (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica centrada en terapias dirigidas para el cáncer de mama, ha anunciado nuevas concesiones de opciones sobre acciones para seis empleados. Las concesiones, aprobadas por el Comité de Compensación bajo el Plan de Inducción 2022 de la empresa, suman 285,000 acciones con un precio de ejercicio de 5.96 $ por acción.
Las opciones sobre acciones presentan un programa de adquisición de cuatro años, con el 25% adquiriéndose en el primer aniversario y el 75% restante en 36 cuotas mensuales iguales durante los siguientes tres años. Las opciones tienen un plazo de 10 años y están condicionadas a la continuidad en el empleo. Esta concesión se realizó de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivo para los nuevos empleados que se incorporan a la empresa.
Olema Pharmaceuticals (Nasdaq: OLMA), 유방암을 위한 표적 치료에 중점을 둔 임상 단계의 생명공학 회사는 6명의 직원에게 새로운 주식 옵션을 부여했다고 발표했습니다. 이 부여는 회사의 2022년 유도 계획에 따라 보상위원회에서 승인되었으며, 총 285,000주로 주당 5.96 달러의 행사가로 이루어져 있습니다.
이 주식 옵션은 4년의 베스팅 일정을 가지고 있으며, 첫 해 기념일에 25%가 베스팅되고, 나머지 75%는 다음 3년 동안 36개월의 동일한 월별 분할로 베스팅됩니다. 이 옵션은 10년의 기간을 가지며, 지속적인 고용을 조건으로 합니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 회사에 합류하는 신규 직원에 대한 유도책으로 이루어졌습니다.
Olema Pharmaceuticals (Nasdaq: OLMA), une entreprise biopharmaceutique en phase clinique axée sur les thérapies ciblées pour le cancer du sein, a annoncé de nouvelles attributions d'options d'achat d'actions à six employés. Les attributions, approuvées par le Comité de Rémunération dans le cadre du Plan d'Induction 2022 de l'entreprise, totalisent 285 000 actions avec un prix d'exercice de 5,96 $ par action.
Les options d'achat d'actions présentent un calendrier d'acquisition de quatre ans, avec 25 % pouvant être acquis lors du premier anniversaire et les 75 % restants pouvant être acquis en 36 versements mensuels égaux sur les trois années suivantes. Les options ont une durée de 10 ans et sont conditionnées à une emploi continu. Cette attribution a été réalisée conformément à la Règle de Cotation Nasdaq 5635(c)(4) comme incitation pour les nouveaux employés rejoignant l'entreprise.
Olema Pharmaceuticals (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien für Brustkrebs konzentriert, hat neue Aktienoptionszuteilungen an sechs Mitarbeiter angekündigt. Die Zuteilungen, die vom Vergütungsausschuss im Rahmen des Unternehmens 2022 Incentive-Plans genehmigt wurden, umfassen insgesamt 285.000 Aktien mit einem Ausübungspreis von 5,96 $ pro Aktie.
Die Aktienoptionen unterliegen einem vierjährigen Vesting-Plan, wobei 25 % nach dem ersten Jubiläum und die verbleibenden 75 % in 36 gleichen monatlichen Raten über die nächsten drei Jahre fällig werden. Die Optionen haben eine Laufzeit von 10 Jahren und sind an eine kontinuierliche Anstellung gebunden. Diese Zuteilung wurde gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für neue Mitarbeiter, die dem Unternehmen beitreten, vorgenommen.
- Successful attraction of new talent with equity compensation package
- Company maintains ability to offer competitive compensation through stock options
- Potential future dilution of existing shareholders through stock option grants
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 285,000 shares of the Company's common stock, effective as of February 3, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
How many shares were granted in Olema's (OLMA) February 2025 stock option grant?
What is the exercise price for OLMA's February 2025 stock option grants?
What is the vesting schedule for OLMA's February 2025 inducement grants?
How long is the term of OLMA's February 2025 stock option grants?
Under which plan were OLMA's February 2025 stock options granted?
